Oregon DFR further states the Ninth Circuit issued a ruling effective October 31, 2025 overturning that decision, requiring the department to “resume collection of mandatory price increase reports from manufacturers.” The bulletin is directed to all manufacturers of prescription drugs subject to the Oregon program. For insurance industry professionals in Oregon – including insurers, brokers, MGAs, underwriters, and compliance teams – the only implication explicitly set out is Oregon DFR’s statement that it is resuming collection of mandatory manufacturer price increase reports, with Bulletin DFR 2024-3 no longer in effect.
Oregon DFR withdraws 2024 suspension bulletin and resumes mandatory drug price increase reporting
By Awais
